Semaglutide is found to be efficient for weight loss in patients with overweight or obesity with
diabetes mellitus (DM). With a wide range of adverse events reported, the efficacy and safety …

Background The weight loss benefit of semaglutide in patients with diabetes is well-
documented, but its clinical utility in treating obesity among patients without diabetes is less …

Background Research on semaglutide's effect on weight loss has been largely focused on
Type 2 Diabetics. No meta-analyses of semaglutide's efficacy in non-diabetic individuals …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly
semaglutide among adults with overweight or obesity. Methods We searched multiple …

Introduction Semaglutide shows significant performance on weight reduction in several
clinical trials. However, it is not clear what kind of administration frequency or dosage will …

Purpose Semaglutide has demonstrated safe and effective weight loss for overweight and
obesity, including participants with concomitant type 2 diabetes mellitus (T2DM), in …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

What is known and objective The purpose of this review paper is to review the efficacy and
safety of subcutaneous semaglutide, marketed as Wegovy, a glucagon‐like peptide‐1 …

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at
doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To …